Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066219 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of BRM421 for Dry Eye Syndrome
A Phase 2 study, sponsored by BRIM Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
NCT03066219 is a Phase 2 study that has completed, run by BRIM Biotechnology. The registered enrollment target is 157 participants.
The verdict
NCT03066219, a Phase 2 study, has completed, sponsored by BRIM Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
Study Summary
The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
Interventions
- DRUG Placebo
- DRUG BRM421
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2017-02-07 |
| Est. Completion | 2017-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03066219
The ClinicalTrials.gov registry entry for NCT03066219 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BRIM Biotechnology, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03066219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03066219 about?
NCT03066219 is a clinical study titled "Safety and Efficacy of BRM421 for Dry Eye Syndrome". The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
What is the current status of trial NCT03066219?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2017-02-07. Estimated completion is 2017-06-28.
What interventions are being tested in trial NCT03066219?
The interventions under investigation include: Placebo (DRUG), BRM421 (DRUG).
Who is sponsoring clinical trial NCT03066219?
This trial is sponsored by BRIM Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.